<DOC>
	<DOCNO>NCT01218659</DOCNO>
	<brief_summary>Study compare efficacy safety AT1001 enzyme replacement therapy ( ERT ) male female patient Fabry disease currently receive ERT AT1001-responsive GLA mutation .</brief_summary>
	<brief_title>Study Compare Efficacy Safety Oral AT1001 Enzyme Replacement Therapy Patients With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Male female age 16 74 diagnosed Fabry disease Confirmed GLA mutation show responsive AT1001 vitro Subject ERT least 12 month Visit 2 Dose level regimen ERT stable 3 month Visit 2 least 80 % currently label dose regimen time period GFR ≥ 30mL/min/1.73 m2 Subjects take angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) must stable dose least 4 week Visit 1 Women become pregnant men agree sexually abstinent use medically accept method birth control throughout duration study 30 day last dose study medication * For site Italy : Women become pregnant men , agree plan ( partner plan ) his/her physician birth control strategy ( method ) order avoid pregnancy throughout duration study 30 day last dose study medication Subject willing able provide write informed consent assent applicable Subject undergone , schedule undergo , kidney transplantation solid organ transplantation Subject regular dialysis specifically treatment chronic kidney disease Subject document transient ischemic attack , stroke , unstable angina , myocardial infarction within 3 month Visit 1 Subject clinically significant unstable cardiac disease opinion investigator ( e.g. , cardiac disease require active management , symptomatic arrhythmia , unstable angina , NYHA class III IV congestive heart failure ) Pregnant breastfeed History allergy sensitivity study medication ( include excipients ) iminosugars ( e.g. , miglustat , miglitol ) Subject absolute contraindication iohexol and/or inability undergo iohexol GFR test Subject require treatment Glyset® ( miglitol ) , Zavesca® ( miglustat ) Subject receive investigational/experimental drug , biologic device within 30 day Visit 1 Any intercurrent illness condition may preclude subject fulfil protocol requirement suggest investigator subject may unacceptable risk participate study Otherwise unsuitable study , opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Fabry Disease</keyword>
</DOC>